Compare American International Group Inc (AIG) vs CVS Health Corp (CVS) Price & Performance

AIG trades at $78.78, down 1.49% on the day, with a neutral technical stance as RSI readings near 42 suggest balanced momentum. The stock shows solid fundamentals with a P/E of 14.38 and recent earnings beats, including Q2 2026 EPS of $2.00 versus $1.92 expected. Revenue stability around $26.8 billion in 2025 and a net income margin of 11.88% reflect disciplined underwriting and expense control, though investment income headwinds persist. Analyst consensus price target is $88.90, implying potential upside, supported by a 39% buy rating among coverage.

Outlook remains cautiously optimistic given earnings consistency and undervaluation relative to peers, but risks include competitive pricing pressure and macroeconomic volatility affecting insurance demand. The dividend yield of approximately 2.5% adds income appeal, yet high beta exposure may lead to amplified swings in broader market downturns, warranting monitoring of Q3 2026 results for sustained growth catalysts.

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.